IL8 Antibody Blocking peptide

Interleukin-8, IL-8, C-X-C motif chemokine 8, Chemokine (C-X-C motif) ligand 8, Emoctakin, Granulocyte chemotactic protein 1, GCP-1, Monocyte-derived neutrophil chemotactic factor, MDNCF, Monocyte-derived neutrophil-activating peptide, MONAP, Neutrophil-activating protein 1, NAP-1, Protein 3-10C, T-cell chemotactic factor, MDNCF-a, GCP/IL-8 protein IV, IL8/NAP1 form I, Interleukin-8, (Ala-IL-8) 77, GCP/IL-8 protein II, IL-8 (1-77), IL8/NAP1 form II, MDNCF-b, IL-8 (5-77), IL-8 (6-77), (Ser-IL-8) 72, GCP/IL-8 protein I, IL8/NAP1 form III, Lymphocyte-derived neutrophil-activating factor, LYNAP, MDNCF-c, Neutrophil-activating factor, NAF, IL-8 (7-77), GCP/IL-8 protein V, IL8/NAP1 form IV, IL-8 (8-77), GCP/IL-8 protein VI, IL8/NAP1 form V, IL-8 (9-77), GCP/IL-8 protein III, IL8/NAP1 form VI, CXCL8, IL8

The synthetic peptide sequence used to generate the antibody orb1928399 was selected from the C-term region of human IL8. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.